medical_device_innovation

Atlanta and Carlsbad, Calif. – September 21, 2026 -- Field Medical, Inc. reported 12-month outcomes from its first-in-human Field PULSE trial showing 94.2% per-vein durability for pulmonary vein isolation using an optimized waveform, with results published in JACC: Clinical Electrophysiology and presented as a Late-Breaking Clinical Trial at HRX Live 2026.

Subsecond ablation cuts median procedure time to 13 minutes

The trial recorded a 13-minute median elapsed pulmonary vein isolation (PVI) ablation time, with a fastest case completed in 7.7 minutes. Field Medical's high-voltage focal pulsed field ablation (PFA) architecture, delivered through its FieldForce PFA System, applies energy in under 200 milliseconds per point, reducing the need for prolonged catheter stability during atrial procedures.

Boston – September 19, 2026 -- Three Harvard University students have won the U.S. National title at the James Dyson Award 2026 for Rumble Rims, an infrared eye-tracking headset designed to screen young athletes for possible concussions in about 60 seconds. Radhika Saran, Cleo Pontone, and Sophia DeVito take home $6,500 in national prize money to fund further development of the device.

Lexington, S.C. – September 14, 2026 -- ElectroWire Medical's FDA-cleared LightningWire Transseptal Puncture System has completed its first six clinical cases at Spartanburg Medical Center in Spartanburg, South Carolina, with zero complications reported.

Six procedures spanned mitral repair, LAA occlusion and pulsed field ablation

The case mix included one mitral valve repair, one left atrial appendage occlusion, and four pulsed field ablations, performed by structural interventional cardiologist Dr. Nalin Srivastava and cardiac electrophysiologist Dr. David Rodak. The team used four different transseptal introducers and two different electrosurgical generators during the cases, testing the device's compatibility with equipment already in operator inventories.

Shanghai – September 09, 2026 -- Pulnovo Medical's pulmonary artery denervation (PADN) system reduced the risk of clinical worsening by 51% in patients with pulmonary hypertension linked to left heart disease (PH-LHD), according to results from the PADN-HF-PH trial presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in The New England Journal of Medicine.

Trial enrolled 264 patients across multiple centers under academician Yaling Han

The multicenter, randomized controlled study, led by academician Yaling Han of the General Hospital of Northern Theater Command, evaluated PADN as an add-on to guideline-directed medical therapy (GDMT) versus GDMT alone. Corresponding authors on the NEJM paper include Professor Shao-Liang Chen of Nanjing First Hospital and Professor Gregg W. Stone of Mount Sinai Hospital.